Vontobel Holding Ltd. Argenx Se Transaction History

Vontobel Holding Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$356.95 - $413.29 $24,986 - $28,930	-70 Reduced 11.51%	538 $211,000
Q4 2023 Jun 03, 2024	BUY	$338.91 - $506.01 $14,573 - $21,758	43 Added 7.61%	608 $231,000
Q4 2023 Jan 29, 2024	BUY	$338.91 - $506.01 $206,057 - $307,654	608 New	608 $231,000
Q2 2023 Jun 03, 2024	BUY	$360.14 - $422.58 $9,723 - $11,409	27 Added 5.02%	565 $220,000
Q2 2023 Jul 24, 2023	BUY	$360.14 - $422.58 $203,479 - $238,757	565 New	565 $220,000
Q2 2021 Aug 06, 2021	SELL	$257.11 - $319.92 $1.33 Million - $1.66 Million	-5,181 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$268.3 - $380.31 $538,478 - $763,282	-2,007 Reduced 27.92%	5,181 $1.43 Million
Q4 2020 Feb 12, 2021	BUY	$248.13 - $308.36 $1.78 Million - $2.22 Million	7,188 New	7,188 $2.64 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.